Chimerix to Announce Third Quarter 2019 Financial Results and Provide an Operational Update on November 5, 2019
October 29 2019 - 8:00AM
Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused
on accelerating the development of innovative medicines to treat
patients with cancer and other serious diseases, today announced
that it will host a live conference call and audio webcast on
Tuesday, November 5, 2019 at 8:30 a.m. ET to report financial
results for the third quarter ended September 30, 2019, and to
provide an operational update.
To access the live conference call, please dial (877) 354-4056
(domestic) or (678) 809-1043 (international) at least five minutes
prior to the start time, and refer to conference ID 1693898. A live
audio webcast of the call will also be available on the Investors’
section of the Company's website, www.chimerix.com. An archived
webcast will be available on the Chimerix website approximately two
hours after the event.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. The two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
Dociparstat sodium is a glycosaminoglycan biologic derived from
porcine heparin that has low anticoagulant activity but retains the
ability to inhibit activities of several key proteins implicated in
the retention and viability of AML blasts and leukemic stem cells
in the bone marrow during chemotherapy (e.g., CXCL12, selectins,
HMGB1). Mobilization of AML blasts and leukemic stem cells
from the bone marrow has been associated with enhanced
chemosensitivity and may be a primary mechanism accounting for the
observed increases in EFS and OS in Phase 2 with DSTAT versus
placebo. Randomized Phase 2 data suggests that DSTAT may also
accelerate platelet recovery post chemotherapy via inhibition of
platelet factor 4, a negative regulator of platelet production that
impairs platelet recovery following chemotherapy. BCV is a lipid
conjugate DNA polymerase inhibitor in development as a medical
countermeasure for smallpox. For further information, please
visit the Chimerix website,www.chimerix.com
CONTACT:
Investor Relations: Michelle LaSpaluto
919-972-7115ir@chimerix.com
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024